Kunal Mahajan: Lipoprotein(a) and LDL-C Target Attainment in ACS Patients
Kunal Mahajan, Director and Chief Interventional Cardiologist at Himachal Heart Institute, shared a post on X about a recent article he and his colleagues co-authored, adding:
“Happy to share our study in the Journal of Clinical Lipidology.
In ACS patients treated with triple oral lipid-lowering therapy, lipoprotein(a) increased significantly after ACS, and higher baseline lipoprotein(a) predicted failure to achieve low-density lipoprotein cholesterol less than fifty milligrams per deciliter at one month.”
Title: Changes in Lipoprotein(a) and Their Association With LDL-C in ACS Patients Treated with Triple Oral Lipid-Lowering Therapy
Authors: Kunal Mahajan, Nitin Mahajan, Jai Bharat Sharma, Surender Himral, Tanuj Bhatia, Deep Dutta
Read the Full Article on Journal of Clinical Lipidology
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 24, 2026, 16:09Jimi Olaghere: The Future of Sickle Cell Disease Research Starts With Collaboration
-
Jun 24, 2026, 16:03Von Willebrand Disease as a Common Yet Under-Recognised Bleeding Disorder – EHC
-
Jun 24, 2026, 15:57Maia Meier: Women with Bleeding Disorders Reach the Summit of Mont Blanc
-
Jun 24, 2026, 15:40Annette Bowyer: The Emerging Role of Extravascular Factor VII in Haemostasis
-
Jun 24, 2026, 13:50Tijjani Balas: Why Early Detection of DVT Matters
-
Jun 24, 2026, 13:43Brandon Michael Henry: Interpreting Complement Activation After AAV Gene Therapy
-
Jun 24, 2026, 13:37Heba Youssef: Heparin-Induced Thrombocytopenia – The Prothrombotic Emergency You Cannot Miss
-
Jun 24, 2026, 13:32Jecko Thachil: Understanding the Clinical Spectrum of Vitamin B12
-
Jun 24, 2026, 13:32Namrata Singh: Beyond Low Platelets – Understanding What Triggers ITP